Susceptibility to smoking related larynx cancer has been suggested to be associated with genetically determined differences in the ability to detoxify carcinogens present in tobacco smoke. The genetic polymorphisms of glutathione S-transferases, involved in the metabolic inactivation of, for example, tobacco derived carcinogens, have been recognized as potential risk modifiers in various environmentally induced malignancies, including larynx cancer. We employed PCR-based methods to determine the distribution of the GSTM1 and GSTT1 null genotypes in 171 larynx cancer patients and 180 controls to examine further their potential role in individual susceptibility to this neoplasm. The GSTM1 null genotype was found in 49.1% of the cases and 57.7 % of the controls and the GSTT1 null genotype in 17.5 % of the cases and 21.7% of the controls, respectively. Larynx cancer risk associated with the lack of GSTM1 (OR=0.7; 95% CI: 0.5-1.1) or GSTT1 (OR = 0.8; 95 % CI: 0.5-1.3) was not significantly affected by age, smoking status, or cancer progression. Although this study thus suggests no role for the GSTM1 and GSTT1 gene polymorphisms in individual susceptibility to smoking-related larynx cancer, due to its relatively small sample size more data are required before any definite conclusions can be drawn.